Barrington Research Maintains Outperform on Surmodics, Raises Price Target to $69
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky maintains an Outperform rating on Surmodics (NASDAQ:SRDX) and raises the price target from $60 to $69.
June 21, 2023 | 4:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barrington Research maintains an Outperform rating on Surmodics and raises the price target from $60 to $69.
The raised price target by Barrington Research indicates a positive outlook for Surmodics. This news is likely to have a positive impact on the stock price in the short term as it shows increased confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100